Coronary atherosclerotic heart disease
Conditions
Interventions
Non-exposed group (Without receiving PCSK9 inhibitor therapy):none
Exposed group (Receiving PCSK9 inhibitor therapy):none
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Age= 18 years old. 2) ECOG PS 0 or 1; 3) patients with malignant tumors, treated with ICIs; 4) Have been diagnosed with coronary atherosclerotic heart disease, and the overall risk assessment of ASCVD is high risk or above; 5) Able to comply with the protocol for the duration of the study. 6) Provide written informed consent prior to entry into the study, and the patient has understood that the study can be withdrawn at any time without any loss.
Exclusion criteria
Exclusion criteria: 1) Patients with severe dysfunction of important organs such as heart, liver, kidney, and lung. 2) Allergy to iodine or contrast media. 3) Severe water and electrolyte disorders. 4) Presence of coagulation dysfunction. 5) Those who have gastrointestinal bleeding within two weeks before enrollment, or who are judged by the investigator to have a high risk of bleeding. 6) There is an underlying medical condition that, in the opinion of the investigator, is not conducive to the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major adverse cardiovascular events; | — |
Secondary
| Measure | Time frame |
|---|---|
| duration of response;Progression-free survival;Overall survival;Drug safety; | — |
Countries
China
Contacts
Public ContactCheng Leilei
Zhongshan Hospital, Fudan University
Outcome results
None listed